Literature DB >> 25323083

Long term rehabilitation management and outcome of anti-NMDA receptor encephalitis: case reports.

Laura J Bach.   

Abstract

BACKGROUND: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an auto immune-disorder. It is a life threatening condition that typically presents with viral illness, headaches, severe psychiatric symptoms, seizures, behavioural changes, decreasing levels of unconsciousness and progressive unresponsiveness, cognitive impairment, abnormal movements (e.g., dyskinesia), ataxia and hypoventilation.
OBJECTIVE: This paper describes the long term outcome and rehabilitation management of patients with NMDAR encephalitis and highlights the diverse outcome of this condition and the unique and individual long term management needs associated with this disorder.
METHODS: This is a case report study of three different patients with NMDAR encephalitis. All three cases are young women, two of whom presented with ovarian teratoma. Patient KH is the most impaired and was resident in a slow stream rehabilitation care home and presented with challenging behaviour. Patients RM and OA both lived in the community and presented with similar anxieties but diverse levels of cognition and motivation. A review of the literature is provided summarizing the disorder, interventions, management and challenges of this varied and complex condition. Standard neuropsychological tests and questionnaires to assess community integration (BICRO-39), quality of life (QOLIBRI-OS) and mood (HADS) were administered.
RESULTS: Positive outcomes were achieved for all three patients using a variety of interventions which included behavioural management, family psycho-education and an integrated holistic multi-disciplinary team community approach. Memory and executive deficits were persistent in the long term and severity of impairments showed wide variability between patients. Emotional distress and behavioural difficulties were prominent and persistent and had a pronounced impact on rehabilitation. Continence issues were also a major factor impacting on the rehabilitation.
CONCLUSIONS: Long term integrated and multi-disciplinary input by a variety of therapies and health disciplines is required in order to improve the long term outcome and quality of life for NMDAR patients and their families, and ultimately leads to improved positive outcomes. Each of these cases had markedly differing cognitive profiles suggesting that in the context of long term rehabilitation outcome, cognition may have less valence than emotional and behavioural factors. Guidelines and standardised procedures for ethical issues and counselling for iatrogenic infertility should be developed and integrated into long term programmes of rehabilitation care.

Entities:  

Keywords:  BICRO; NMDAR; QOLIBRI; cognition; community integration; fertility; quality of life; rehabilitation outcome

Mesh:

Year:  2014        PMID: 25323083     DOI: 10.3233/NRE-141176

Source DB:  PubMed          Journal:  NeuroRehabilitation        ISSN: 1053-8135            Impact factor:   2.138


  3 in total

1.  Voxel-based analysis and multivariate pattern analysis of diffusion tensor imaging study in anti-NMDA receptor encephalitis.

Authors:  Yanli Liang; Luhui Cai; Xia Zhou; Huanjian Huang; Jinou Zheng
Journal:  Neuroradiology       Date:  2019-11-29       Impact factor: 2.804

2.  Gray matter atrophy and corresponding impairments in connectivity in patients with anti-N-methyl-D-aspartate receptor encephalitis.

Authors:  Yuanyuan Guo; Xinyi Lv; Juanjuan Zhang; Chenglong Li; Ling Wei; Nong Zhou; Jinping Xu; Yanghua Tian; Kai Wang
Journal:  Brain Imaging Behav       Date:  2022-08-23       Impact factor: 3.224

3.  Anti-N-Methyl-D-Aspartate-Receptor Encephalitis: A 10-Year Follow-Up.

Authors:  Sophie Meixensberger; Ludger Tebartz van Elst; Tina Schweizer; Simon J Maier; Harald Prüss; Bernd Feige; Dominik Denzel; Kimon Runge; Kathrin Nickel; Miriam Matysik; Nils Venhoff; Katharina Domschke; Horst Urbach; Evgeniy Perlov; Dominique Endres
Journal:  Front Psychiatry       Date:  2020-05-15       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.